Crohn's Disease - Wake Research

Crohn’s Disease

Explore a Clinical Research Study for People with Active Crohn’s Disease

Ozanimod (also known as RPC-1063) is an investigational medication being studied for individuals experiencing moderately to severely active Crohn’s disease. Ozanimod is an oral (taken by mouth) medication. In this clinical study, the investigational medication is taken once daily.

To qualify, you must:

  • Are 18 to 75 years of age.
  • Have been diagnosed with active Crohn’s disease (confirmed by endoscopy evidence) for at least three months.
  • Have not improved on, have lost response to, or have not been able to tolerate at least one prior Crohn’s disease medication

To qualify, you must:

  • Study-related medication at no cost
  • Study-related medical exams at no cost
  • Compensation for time and travel

Why Participate?

Contribute to the advancement of medical knowledge and treatments, while receiving expert medical care under close supervision.


The M3 Wake Research Network has powered innovation with over 9,100 Successful Clinical Trials in patients from 6 months to 85 years.


Patient safety is paramount with strict protocols and ethical guidelines, minimizing risks and ensuring thorough monitoring throughout the trial.

Wake Research

Study Hotline 

Main Office

Our Hours
Mon-Fri: 7:30AM to 5PM

Our Location 
3100 Duraleigh Rd, Suite 304
Raleigh, NC 27612